4-chloro-1-ethyl-1H-pyrazolo<3,4-b>pyridine-5-carbonyl chloride | 52833-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 4-chloro-1-ethyl-1H-pyrazolo<3,4-b>pyridine-5-carbonyl chloride
• 英文别名: 4-Chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid chloride；4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl chloride；4-chloro-1-ethylpyrazolo[3,4-b]pyridine-5-carbonyl chloride
• CAS: 52833-03-1
• 化学式: C₉H₇Cl₂N₃O
• 分子量: 244.08
• InChiKey: KQZOAQNTKVFCPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-chloro-1-ethyl-1H-pyrazolo<3,4-b>pyridine-5-carbonyl chloride 在 氨 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 90.0h， 生成 4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide
  参考文献：
  名称：

  [EN] PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
  [FR] COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHODIESTERASE

  摘要：

  公开号：

  WO2004024728A3
• 作为产物：
  描述：

  1-乙基-4-羟基-1H-吡唑并[3,4-b]吡啶-5-羧酸乙酯 在 sodium hydroxide 、 氯化亚砜 作用下， 以 水 为溶剂， 生成 4-chloro-1-ethyl-1H-pyrazolo<3,4-b>pyridine-5-carbonyl chloride
  参考文献：
  名称：

  Amino derivatives of pyrazolopyridine carboxamides

  摘要：

  揭示了具有以下结构式的吡唑并[3,4-b]吡啶-5-羧酰胺的4-氨基衍生物。这些新化合物可用作镇静、镇痛和降压剂。

  公开号：

  US03966746A1

文献信息

• [EN] PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO[3,4-b]PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2005090353A1

  公开（公告）日：2005-09-29

  The invention relates to a compound of formula (I) or a salt thereof: formula (I) wherein: R1 is Et, n-Pr, i-Pr, C2fluoroalkyl, or -CH2CH2OH; R2 is H, Me, Et, n-Pr, i-Pr, C1-2fluoroalkyl, cyclopropyl or (cyclopropyl)methyl-; and NHR3 has the sub-formula (nhr3): formula (nhr3) wherein R3a is methyl or ethyl; R3b is H, methyl or ethyl; R3c is H, methyl or ethyl, R3d is H, methyl or ethyl, and R3e is H or methyl, provided that: (a) R3b is methyl or ethyl; and/or (b) R3c and R3d are independently methyl or ethyl; and provided that: (c) when R3c is ethyl and/or when R3d is ethyl and/or when R3e is methyl, then: R3a is methyl and/or R3b is a hydrogen atom (H) or methyl. NHR3 can for example be [(1S)-1,2-dimethylpropyl]amino or t-butylamino. The invention also relates to the use of these pyrazolo[3,4 b]pyridine compounds in therapy, as inhibitors of phosphodiesterase type IV (PDE4), and relates to their use in the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis.

  该发明涉及公式（I）的化合物或其盐：公式（I）其中：R1为Et、n-Pr、i-Pr、C2氟烷基或-CH2CH2OH；R2为H、Me、Et、n-Pr、i-Pr、C1-2氟烷基、环丙基或（环丙基）甲基-；NHR3具有亚公式（nhr3）：公式（nhr3）其中R3a为甲基或乙基；R3b为H、甲基或乙基；R3c为H、甲基或乙基，R3d为H、甲基或乙基，R3e为H或甲基，条件是：（a）R3b为甲基或乙基；和/或（b）R3c和R3d独立为甲基或乙基；并且条件是：（c）当R3c为乙基和/或当R3d为乙基和/或当R3e为甲基时，则：R3a为甲基和/或R3b为氢原子（H）或甲基。NHR3可以例如是[(1S)-1,2-二甲基丙基]氨基或叔丁基氨基。该发明还涉及将这些吡唑并[3,4 b]吡啶化合物用于治疗，作为磷酸二酯酶IV（PDE4）的抑制剂，并涉及它们在治疗和/或预防炎症和/或过敏疾病如慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎或过敏性鼻炎中的用途。
• [EN] PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR<br/>[FR] COMPOSE DE PYRAZOLO[3,4-B]PYRIDINE, ET SON UTILISATION EN TANT QU'INHIBITEUR DE PDEA4
  申请人：GLAXO GROUP LTD

  公开号：WO2005090352A1

  公开（公告）日：2005-09-29

  The invention provides 4-[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carb oxamide, which is the compound of formula (I), or a salt thereof. The invention also provides the use of said compound or a pharmaceutically acceptable salt thereof as an inhibitor of phosphodiesterase type IV (PDE4), for example in the treatment and/or prophylaxis of an inflammatory and/or allergic disease, cognitive impairment or depression in a mammal. In particular, the invention provides the use of the compound or pharmaceutically acceptable salt in the treatment and/or prophylaxis of atopic dermatitis in a mammal, for example by external topical administration to the mammal such as a human. Pharmaceutical compositions containing said compound or salt, in particular suitable for external topical administration, are also provided.

  本发明提供了化合物4-[1-(氨基甲酰基)-4-哌啶基]氨基}-N-[(3,4-二甲基苯基)甲基]-1-乙基-1H-吡唑并[3,4-b]吡啶-5-羧酰胺，该化合物为式(I)的化合物或其盐。本发明还提供了该化合物或其药学上可接受的盐作为磷酸二酯酶IV型（PDE4）抑制剂的用途，例如在哺乳动物中治疗和/或预防炎症和/或过敏性疾病、认知障碍或抑郁症。特别地，本发明提供了该化合物或其药学上可接受的盐在哺乳动物中治疗和/或预防特应性皮炎的用途，例如通过外部局部给药给哺乳动物，如人类。还提供了含有该化合物或盐的制药组合物，特别适用于外部局部给药。
• Fused pyridine inhibitors of cGMP phosphodiesterase
  申请人：Bristol-Myers Squibb Co.

  公开号：US06326379B1

  公开（公告）日：2001-12-04

  Compounds of the formulas are useful as inhibitors of cGMP PDE, especially type V.

  这个句子的翻译是：具有这些化学式的化合物可用作cGMP PDE的抑制剂，特别是V型。
• Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
  申请人：Allen George David

  公开号：US20060089375A1

  公开（公告）日：2006-04-27

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及一种化合物或其盐，其化学式为（I）：其中：R1为C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基；R2为氢原子（H），甲基或C1氟烷基；R3为可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚式（aa），（bb）或（cc）的可选取代的杂环基；其中n1和n2独立地为1或2；且其中Y为O，S，SO2或NR10；或者R3为双环基（dd）或（ee）：其中X为NR4R5或OR5a。该化合物为磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了使用化合物（I）或其药学上可接受的盐制造药物，用于治疗和/或预防哺乳动物（例如人类）的炎症和/或过敏性疾病，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
  申请人：Allen George David

  公开号：US20070111995A1

  公开（公告）日：2007-05-17

  The invention provides pyrazolo[3,4-b]pyridine compounds of formula (I) having a —C(O)—NH—C(R 4 )(R 5 )-aryl substituent at the 5-position of the pyrazolo[3,4-b]pyridine ring system wherein at least one of R 4 and R 5 is not a hydrogen atom (H) compound or a salt thereof: wherein Ar has the sub-formula (x) or (z). These compounds are useful as inhibitors of PDE4.

  本发明提供了式(I)的吡唑并[3,4-b]吡啶化合物，其在吡唑并[3,4-b]吡啶环系的5位具有—C(O)—NH—C(R4)(R5)-芳基取代基，其中R4和R5中至少有一个不是氢原子（H）化合物或其盐：其中Ar具有亚式（x）或（z）。这些化合物可用作PDE4的抑制剂。